Catalent Pharma Solutions said today it was undertaking a major expansion of activity in China by acquiring a Chinese-based maker of nutritional softgel products, and joining with a second on a separate joint venture focused on clinical trial supplies. Catalent said it will acquire a majority stake in Haining-based, privately-held Zhejiang Jiang Yuan Tang Biotechnology for an undisclosed price. “Catalent intends to work with regulators for future expansion into OTC and prescription softgel manufacturing in China,” the company said in a statement. Read the full story here.